Homepage

Often perinatal fistulae resist treatment, both with medications and through treatment with a seton, a thread that is placed to promote drainage and healing. Currently ...

This story originally appeared on the In the Loop blog. ____________________ Last July, Jennifer Gutman told Toledo, Ohio’s 13abc Action News that the day doctors diagnosed ...

When current treatment isn’t enough, patients at Mayo Clinic often are among the first to benefit from innovative therapies, new techniques and technologies. For ...

The American Society of Transplantation (AST) awarded its highest honor, the Lifetime Achievement Award, to Thomas Gonwa, M.D. at the recent American Transplant Congress in ...

New research at Mayo Clinic is bringing hope to hundreds of thousands of Crohn’s disease patients. Their extreme pain from complications is both physical ...

Researchers on Mayo Clinic’s Florida campus have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent. The combination therapy worked in a laboratory study to stop lung adenocarcinoma associated with mutation of the KRAS gene. The study will be published in the March 14 issue of Cancer Cell. “If our approach works in KRAS-mediated lung adenocarcinoma, it may work in other KRAS-mediated cancers, such as pancreaticand colon cancers, as well as other cancer types,” says the study’s senior author, Alan P. Fields, Ph.D., a cancer biologist and the Monica Flynn Jacoby Professor of Cancer Research in the Department of Cancer Biology at Mayo Clinic in Florida. Based on this and other preclinical research from Dr. Fields’ team, Mayo Clinic is conducting early-phase clinical trials to test the effectiveness of auranofin alone and in targeted combinations in patients with KRAS-mediated lung adenocarcinoma, ovarian cancer, and another common lung cancer called lung squamous cell carcinoma. https://www.youtube.com/watch?v=W1LJHSn8zug

The World Stem Cell Summit, December 10-12 in Atlanta, unites and educates the global stem cell community. With more than 1,200 attendees from more than 40 countries, the annual World Stem Cell Summit’s interdisciplinary agenda explores disease updates, research directions, cell standardization, regulatory pathways, reimbursements, financing, venture capital and economic development. Throughout the week, the Mayo Clinic Center for Regenerative Medicine will use social media to connect using the hashtag #WSCS15. At the end of the week, we'll let the tweets, Google+ posts, Flickr photos, Facebook posts and YouTube videos tell the story.

Michael Yaszemski, M.D., Ph.D., physician, orthopedic surgeon and engineer, wants to make it clear that the advances in orthopedic regenerative medicine are the product of teamwork. During his recent talk entitled "Mayo’s History of Military Research and Musculoskeletal Regenerative Medicine of Today," Dr. Yaszemski discussed the recent developments in regenerative orthopedic surgery and took the time to fully credit his team members for the hard work they've done. Since the advent of modern medicine there have been four eras of orthopedic surgery: resection, fusion, replacement and, now, regeneration. Resection was the process used in the very early days of surgery in which damaged joints were removed completely. This alleviated any pain but left patients unstable and unable to move freely. Next came fusion in which an injured joint was removed and the two bones fused together. Fusion gave patients stability but at the cost of mobility. In the 1950s replacement became the primary method thanks to the work done at Mayo Clinic under the guidance of Mark B. Coventry, M.D. During this era an injured joint was replaced with a metal or synthetic joint, which largely restored a patient's mobility. The issue with replacement is that the artificial joints will ultimately deteriorate, requiring repeat surgeries.

FEEL THE BEAT Saturday, October 17, 2015 10 a.m. - 3 p.m. Mayo Clinic Rochester, MN   'Feel the Beat' is a fun-filled day featuring new and exciting research taking place in the Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome (HLHS), connecting families to others in the HLHS community and providing an opportunity to listen to and meet special guest speakers. This year the event will feature Chris Moir, M.D., Mayo Clinic pediatric surgeon who led a team to successfully separate 5-month-old conjoined twins; Ethan Bortnick, a 14-year-old piano prodigy; and Joslynn Jarrett-Skelton, author of Charlie the Courageous. The day also highlights how the HLHS program is making a difference and how the community can come together to increase awareness and support for our HLHS warriors.